Manuel Alba, Chairman of Astera Labs, sold approximately $81.23M in ALAB common stock across multiple transactions in the past 24 hours. The sales were executed through a pre-scheduled 10b5-1 plan and routed through director-linked entities, including an LLC and a trust.
This is a developing story. The full transaction breakdown has not been disclosed, and additional filings may follow.
What it means
A 10b5-1 plan matters here. These plans are set up in advance, when the insider is not in possession of material non-public information, and trades execute automatically on a schedule. That structure removes some of the alarm that would attach to an open-market discretionary sale. Still, $81.23M is a large dollar figure by any measure, and it warrants attention.
Recibe el resumen semanal de ACCE
Rentabilidad de los índices, repaso de las selecciones y los mayores cambios de puntuación, cada domingo. Sin relleno.
The timing lands against a backdrop that makes the valuation question hard to ignore. ALAB currently trades at $394.45, against a 6-model fair value estimate of $63.71 — a gap of 83.8% to the downside. The trailing P/E sits at 296.4 and the forward P/E at 137.0. The analyst consensus target is $272.47, itself well below the current price.
The ACCE score for ALAB is 70/100. The breakdown tells the story clearly: Growth scores 100, Momentum scores 97, Quality comes in at 73, and Value scores 10. That Value score reflects how stretched the current price looks relative to fundamentals, even accounting for the company's genuine operating strength.
And that operating strength is real. Revenue grew 93.4% year over year. Earnings grew 144.4% over the same period. Net margin stands at 26.7% and ROE at 21.1%. Earnings quality is flagged as strong. The 1-year return is 340.1%. This is not a struggling company — it is a fast-growing one trading at a price that already prices in a great deal of future execution.
The FCF yield of 0.4% reflects how much of the market cap sits in future expectations rather than current cash generation.
So the question the Alba sale raises is not whether ALAB is a good business. The data suggests it is. The question is whether the current price leaves room for new buyers, and whether a chairman reducing exposure at this level carries a signal beyond the mechanics of a pre-scheduled plan.
No company comment has been issued. Watch for additional Form 4 filings in the coming days, which will clarify the full scope of the transactions and whether further sales are planned under the same plan.
For the current price and full score breakdown, visit acceinvestments.com/stocks/ALAB.
ACCE scores thousands of stocks across valuation models matched to each company, with fair value, conviction and the full thesis on every name. Start free, no card required.
